Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Adalimumab Induction for Steroid-Dependent Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
NCT06037811Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) comparing Standard of care group with Adalimumab group (2 arms). Primary endpoints: Percentage of participants on prednisone at 12 weeks and Cumulative prednisone dose at 12 weeks. Started Apr 2024; status: recruiting.
02
Drugs
03
Conditions
Immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA)
Beyond the preview
Go deeper on NCT06037811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037811.